Wuxi Fortune Pharmaceutical is an API manufacturer based in China. It holds 8 active US drug master files across a filed portfolio of 8 molecules. Its filings concentrate with US FDA and MINSA (CR). Its GMP standing is certified by MFDS (Korea) and US FDA. Its most recent recorded inspection, by US FDA, closed on 22 November 2024 as VAI.
NAI means no action indicated, VAI means voluntary action indicated, and OAI means official action indicated.
| Site | FDA FEI |
|---|---|
| China, China | 3005968356 |
| Molecule | Regulators | Docs |
|---|---|---|
| Mitomycin | SFDA (Saudi Arabia), US FDA | 2 |
| Cantharidin | US FDA | 1 |
| Doxercalciferol | US FDA | 1 |
| Mycophenolate Mofetil | US FDA | 1 |
| Mycophenolic Acid | US FDA | 1 |
| Rifapentine | US FDA | 1 |
| Rivastigmine | US FDA | 1 |
| Tacrolimus | US FDA | 1 |
Also appears on these molecule pages
| Regulator | Filings | GMP certificates |
|---|---|---|
| US FDA | 1 | 1 |
| MINSA (CR) | 1 | None |
| MFDS (Korea) | None | 2 |
Answered from this company's own record. Where a register holds nothing, the question is not asked rather than answered with a zero. How we count our figures.
Choose your molecules and target markets. Wuxi Fortune Pharmaceutical comes back tiered against every other supplier able to file there.
Start for freeRanked by shared active ingredients where we have them, otherwise by country and comparable credentials.